Kymera Therapeutics (NASDAQ:KYMR) Given New $112.00 Price Target at Bank of America

Kymera Therapeutics (NASDAQ:KYMR) had its price objective increased by Bank of America from $71.00 to $112.00 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Wednesday, October 8th. Truist Financial boosted their price target on Kymera Therapeutics from $68.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, November 26th. B. Riley upped their price target on Kymera Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Friday, October 24th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $67.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, November 4th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Buy” and a consensus target price of $105.30.

Kymera Therapeutics Price Performance

KYMR opened at $86.88 on Tuesday. The stock has a 50-day moving average price of $62.80 and a 200-day moving average price of $50.90. The firm has a market cap of $6.25 billion, a PE ratio of -24.20 and a beta of 2.28. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The firm had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. As a group, sell-side analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Nello Mainolfi sold 100,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the sale, the chief executive officer owned 660,482 shares of the company’s stock, valued at approximately $58,895,179.94. This represents a 13.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 361,217 shares of company stock worth $25,140,500 in the last ninety days. Insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after acquiring an additional 344,080 shares during the period. Invesco Ltd. increased its stake in shares of Kymera Therapeutics by 36.9% in the 1st quarter. Invesco Ltd. now owns 42,075 shares of the company’s stock worth $1,152,000 after purchasing an additional 11,343 shares in the last quarter. Nuveen LLC bought a new position in Kymera Therapeutics in the 1st quarter worth $3,920,000. Russell Investments Group Ltd. lifted its position in Kymera Therapeutics by 40.0% during the first quarter. Russell Investments Group Ltd. now owns 82,507 shares of the company’s stock valued at $2,258,000 after purchasing an additional 23,584 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics during the first quarter valued at $68,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.